Travere Therapeutics CAO Sells Over $139K in Shares

Insider transaction discloses sale of 4,333 shares by Chief Accounting Officer Sandra Calvin.

Feb. 4, 2026 at 5:31am

Got story updates? Submit your updates here. ›

Travere Therapeutics, Inc. (NASDAQ:TVTX) Chief Accounting Officer Sandra Calvin sold 4,333 shares of the company's stock on February 3rd, 2026 at an average price of $32.12 per share, resulting in a total transaction value of $139,175.96. This sale represents an 8.11% decrease in Calvin's ownership stake in the biopharmaceutical company.

Why it matters

Insider transactions, especially those involving C-suite executives, can provide valuable insights into a company's performance and future prospects. The sale by Travere's CAO may signal a shift in management's outlook or a desire to diversify personal holdings, though the reasons behind the transaction are not explicitly stated.

The details

According to the SEC filing, the 4,333 shares sold by Sandra Calvin represented a portion of her direct ownership in Travere Therapeutics. Following the sale, Calvin still holds 49,080 shares in the company, valued at approximately $1.58 million based on the most recent closing price.

  • The share sale transaction occurred on Tuesday, February 3rd, 2026.

The players

Sandra Calvin

Chief Accounting Officer of Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, dedicated to developing and commercializing therapies for rare kidney and genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

This insider transaction highlights the ongoing changes and activity within Travere Therapeutics as it continues to advance its pipeline of rare disease treatments. While the reasons behind the CAO's share sale are not explicitly stated, it is a notable event that may warrant further monitoring of the company's financial and operational performance.